Table 2b.
Other clinical characteristics of respondents at the 4 study sites (n=400)
| Clinical characteristic | Total (n=400), n (%) | Adherence level of respondents | Pa | |
|---|---|---|---|---|
| Nonadherent (n=209), n (%) | Adherent (n=191), n (%) | |||
| Total medications prescribed for diabetes and comorbid conditions | ||||
| 1-2 | 99 (24.8) | 45 (21.5) | 54 (28.3) | 0.256 |
| 3-4 | 269 (67.3) | 148 (70.8) | 121 (63.4) | |
| ≥5 | 32 (8.0) | 16 (7.7) | 16 (8.4) | |
| Duration of oral hypoglycemic agents prescribed at last attendance (months) | ||||
| 1 | 281 (70.3) | 151 (72.2) | 130 (68.1) | 0.407 |
| 2 | 118 (29.5) | 58 (27.8) | 60 (31.4) | |
| 3 | 1 (0.3) | 0 (0.0) | 1 (0.5) | |
| Type of oral hypoglycemic agents prescribed at last attendance | ||||
| Metformin | 34 (8.5) | 19 (9.1) | 15 (7.9) | 0.547 |
| Glibenclamide | 16 (4.0) | 7 (3.4) | 9 (4.7) | |
| Metformin + glibenclamide | 167 (41.8) | 86 (41.1) | 81 (42.4) | |
| Metformin + glimepiride | 37 (9.2) | 19 (9.1) | 18 (9.4) | |
| Metformin + gliclazide | 18 (4.5) | 9 (4.3) | 9 (4.7) | |
| Metformin + glibenclamide + pioglitazone | 32 (8.0) | 22 (10.5) | 10 (5.2) | |
| Metformin + glimepiride + pioglitazone | 13 (3.3) | 8 (3.8) | 5 (2.6) | |
| Metformin + gliclazide + pioglitazone | 73 (18.3) | 36 (17.2) | 37 (19.4) | |
| Others | 10 (2.5) | 3 (1.4) | 7 (3.7) | |
| Number of oral hypoglycemic agents prescribed at maximum dose | ||||
| 0 | 243 (60.7) | 120 (57.4) | 123 (64.4) | 0.197 |
| 1 | 72 (18.0) | 42 (20.1) | 30 (15.7) | |
| 2 | 82 (20.5) | 44 (21.1) | 38 (19.9) | |
| 3 | 3 (0.8) | 3 (1.4) | 0 (0.0) | |
aP value from Chi-square